Memorial Sloan Kettering Cancer Center is a non-profit, National Cancer Institute (NCI)-designated Comprehensive Cancer Center headquartered at 1275 York Avenue, New York, NY. The main campus hospital, located in Manhattan, provides both inpatient and outpatient facilities. There are 16 additional outpatient facilities in Manhattan (10), Long Island (3), Westchester (1), and New Jersey (2).
The Program for Drug Development in Leukemia conducts phase I clinical trials at the new David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, located at 530 East 74th Street, New York, NY, 10021. Currently, we are not operating out of our regional outpatient locations but are accepting patient transfers.
For patients who are already being treated at Memorial Sloan Kettering Cancer Center, your treating physician can refer you to the Leukemia Service for further treatment and evaluation.
If you are a patient, or a provider who has a patient who may be a good fit for one of our clinical trials, please call 646-608-3749. We can then facilitate record transfer and initial appointments.
The Program for Drug Development in Leukemia is focused solely on phase I clinical trials with clinical research staff who are dedicated to the program. We collaborate with the Center for Hematologic Malignancies and various departments within the hospital to streamline all aspects of clinical trial operations and contribute to scientific discovery within our research labs.